Eli Lilly to resume some coronavirus antibody-drug trials after safety concerns.

Global News

Breaking news & current latest Canadian news headlines; national weather forecasts & predictions, local news videos, money and financial news; sports stats and scores.


Click to play video 'Drug reveals promising results as potential COVID-19 treatment'

WATCH: Drug reveals promising results as potential COVID-19 treatment

Eli Lilly & Co on Wednesday said that other trials of its experimental COVID-19 antibody-drug will continue apace after it paused one ongoing trial of the drug, citing safety concerns.

The paused trial, which Lilly calls ACTIV-3, focused on hospitalized patients. Lilly said it differed from its other trials in some key respects, including the fact that the patients had more serious illness and were being treated with other drugs, including Gilead Sciences Inc’s remdesivir.

Lilly said in a statement that neutralizing antibody drugs such as bamlanivimab, which it is studying in COVID-19 patients, may be less beneficial for hospitalized patients than for those with more mild cases of the disease.

The trial was paused at the request of an oversight board, called a Data Safety and Monitoring Board (DSMB), which also reviews data on other U.S. government-backed studies of COVID-19 medicines. It is not uncommon to pause drug trials to investigate safety concerns, and such actions do not necessarily indicate a serious problem.

Trending Stories

“Lilly trusts the judgment of the independent DSMB and supports its decisions to exercise caution in ensuring the safety of the patients participating in this study,” the company said in a statement.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Lilly said on Tuesday the government-sponsored clinical trial of its COVID-19 antibody treatment, which is similar to one taken by U.S. President Donald Trump, had been paused over safety concerns.

Lilly said earlier this month it was applying for emergency use authorization (EUA) for the antibody-drug, also called LY-CoV555, for patients with mild to moderate COVID-19 based on data from another clinical trial. It is also testing the drug in nursing homes to see if it can prevent staff and residents from getting infected.

View link »

© 2020 Reuters

Related news

NASA spacecraft collects up to 4.5 pounds of asteroid to be sent to Earth

The spacecraft Osiris-Rex won't depart Bennu's neighbourhood until March at the earliest, when the asteroid and Earth are properly aligned.

Twitter Deletes Ex-Malaysian PM's Tweet For Glorifying Attack In France.

Social networking platform Twitter on Thursday removed former Malaysian Prime Minister Mahathir Mohamad's tweet, for violating its rules banning the glorification of violence, shortly after a violent...

Two Indian-Americans Among Joe Biden's Core Advisors: Reporte.

Two prominent Indian-Americans are among Democratic Presidential nominee Joe Biden's "core advisers" who have been guiding him on issues ranging from the coronavirus pandemic, economic recovery to...

Walmart stops displaying guns, ammunition at U.S. stores, citing ‘civil unrest’

The discounter said the items remain available for purchase by customers.

Amid Protests, Walmart Removes Guns From Display At US Stores.

Walmart plans to remove guns and ammunition from its sales floors in the US following unrest in Philadelphia this week, a spokeswoman said Thursday.

New Zealand votes against legalizing cannabis, preliminary results show.

53 per cent voted against legalizing the drug for recreational use and 46 per cent voted in favour, leaving a chance it could still pass once all special votes are counted next week.

US Tops 90,000 Coronavirus Cases In 24 Hours For First Time.

The United States notched a record number of new coronavirus cases on Thursday, for the first time topping 90,000 diagnoses in 24 hours, according to a tally from Johns Hopkins University.

Late iPhone Launch Temporarily Wiped $100 Billion Off Apple's Stock Value.

The late launch of new 5G phones caused Apple Inc's customers to put off buying new devices, leading the company on Thursday to report the steepest quarterly drop in iPhone sales in two years.

Charlie Hebdo to still publish Islam cartoons despite attacks in France.

Its decision to publish new cartoons this week ridiculing its opponents in the Islamic world formed the backdrop for yet another attack Thursday in France, where three people were fatally attacked in a church.

Europe braces for a ‘difficult winter’ as it breaks coronavirus records.

WHO’s European regional director Dr. Hans Kluge said “hospitalizations have risen to levels unseen since the spring” and deaths have sharply risen by more than 30 per cent.

By continuing to browse World News (UAZMI), you acknowledge that you have read the Terms of Use and agree to the use of cookies